Roth Mkm Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Roth Mkm assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $11.00 target price on the stock.

Several other research firms have also issued reports on TLSI. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Oppenheimer initiated coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $12.25.

TriSalus Life Sciences Trading Down 10.9 %

Shares of NASDAQ TLSI opened at $4.01 on Monday. The stock has a market cap of $122.26 million, a price-to-earnings ratio of -1.80 and a beta of 0.49. The stock’s 50-day moving average is $4.38 and its 200 day moving average is $5.85. TriSalus Life Sciences has a 1-year low of $3.32 and a 1-year high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million for the quarter. On average, analysts forecast that TriSalus Life Sciences will post -1.5 EPS for the current fiscal year.

Insider Activity

In related news, CEO Mary T. Szela purchased 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the acquisition, the chief executive officer now directly owns 377,382 shares in the company, valued at approximately $1,962,386.40. The trade was a 2.03 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at about $66,000. MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $184,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $240,000. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $1,184,000. Finally, Duquesne Family Office LLC boosted its position in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.